04/03/2009 11:36

CTL Writes Book Chapter on Validating Reference Samples for Use in Cell-Based Assays

In a new book on cell-based assays, CTL discusses key considerations in validating an ELISPOT assay.

Cellular Technology Limited has contributed a key chapter to the book, Validation of Cell-Based Assays in the GLP Setting: A Practical Guide. This text is one of the latest offerings by Research and Markets, a leading source for international market research and market data.

This book describes the development, optimization and validation of various cell-based assays, such as cytokine ELISPOT and ELISA assays, for which validation procedures have been developed. In addition, it discusses the validation of these assays for select targets using step-by-step instructions. Chapter 9 ("Validating reference samples for comparison in a regulated ELISPOT assay") was written by CTL personnel Magdalena Tary-Lehmann, Christina D. Hamm, and Paul V. Lehmann. In this chapter, they discuss the utility and performance of the ELISPOT method, as well as key considerations in validating such assays.

Validation of Cell-based Assays in the GLP Setting is an invaluable reference source for pharmaceutical companies and biotechnology firms that need to evaluate drug targets derived from genomics and proteomics. It is also a useful reference for companies that use cell-based technologies for biomarker discovery and development.

In addition, the potential of biomarkers to facilitate the development of effective and safe drugs is being recognized as an integral part of all phases of drug development, and cell-based technologies are a critical part of biomarker discovery and development.

 

For more information visit www.researchandmarkets.com/reports/c89231.

News archive

Featured products

CTL QC Sets™

CTL’s Reference Sample QC Sets™ offer outstanding inter-assay control. Use CTL's QC Sets™ not only for validation and protocol setup purposes, but also as internal controls for clinical trials...

CTL QC Sets™

PBMC


show/hide all

fold faq What kind of Class I CEF-peptides are you testing for?
fold faq Can these cells (PBMC) be cultured and for how long? What is the growth rate? How do you culture them?
fold faq What kind of HLA-typing results do you provide?
fold faq What kind of protein-antigens are you testing for?
fold faq What kind of peptide pools are you testing for?
fold faq What kinds of flu strains are used in immune characterization?
fold faq The responses you have seen with the above antigens are for which cytokines?
fold faq What kind of anticoagulant has been used?
fold faq What kind of machine has been used for collection by aphaeresis?
fold faq Are the PBMC samples tested for presence of EBV – sequences by PCR?
fold faq Is there a serological profile of each donor; are the donors EBV-seronegative?
fold faq Can you guarantee continuous delivery of PBMC over a long time span?
fold faq How do you ship these cells?
fold faq What is the viability rate of the cells after thawing?
fold faq What kind of laboratory testings has been done for the LP donors?